推进系统测试:利用多国电子健康数据开展疫苗获益研究——以百日咳疫苗接种为例
ADVANCE公私合作联盟实施并测试了一个分布式网络系统,用于生成欧洲已上市疫苗获益-风险证据。该研究利用四国七个电子数据库的回顾性队列,估算接种无细胞或全细胞百日咳疫苗儿童的百日咳及并发症发病率,队列包含2,886,367名≤5岁儿童,结果显示百日咳发病率随疫苗剂次增加而下降,相关并发症罕见。
要点
- ADVANCE系统可估算疫苗接种后百日咳发病率变化。
- 百日咳发病率随无细胞和全细胞疫苗剂次增加而下降。
- 百日咳相关并发症罕见,相对风险无法可靠估计。
核心结论
- 研究证明ADVANCE系统估算百日咳疫苗接种后百日咳发病率变化具有可行性。
- 更大的样本量可为比较百日咳患儿与非患儿之间的并发症风险提供额外效力。
- 未来可考虑开展疫苗类型特异性效果研究的可行性。
研究设计与样本
- ADVANCE公私合作联盟实施并测试了一个分布式网络系统,用于生成欧洲已上市疫苗获益-风险证据。
- 采用回顾性队列分析,纳入1990年1月至2015年12月接种任何百日咳疫苗的儿童,排除切换疫苗类型或类型未知者。
- 数据来自四国七个电子数据库:丹麦AUH和SSI,西班牙SIDIAP和BIFAP,英国THIN和RCGP RSC,意大利Pedianet。
- 暴露定义为任何百日咳疫苗接种(无细胞或全细胞),随访从首剂后14天开始。
- 队列包含2,886,367名≤5岁儿童;全细胞和无细胞疫苗接种数据分别来自三个和七个数据库。
主要发现
- 百日咳发病率(每10万人年)差异较大,范围在0.15(95%CI:0.12;0.19)至1.15(95%CI:1.07;1.23)之间。
- 百日咳发病率随时间趋势与全国监测数据库确诊百日咳趋势一致。
- 百日咳发病率随全细胞和无细胞疫苗剂次增加而下降。
- 百日咳相关并发症罕见:89例肺炎、7例全身性惊厥、无死亡;其相对风险(与非百日咳相比)无法可靠估计。
局限性
- 百日咳相关并发症罕见(89例肺炎、7例全身性惊厥、无死亡),其相对风险(与非百日咳相比)无法可靠估计。
- 更大的样本量可为比较百日咳患儿与非患儿之间的并发症风险提供额外效力。
- 未来可考虑开展疫苗类型特异性效果研究的可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Accelerated Development of VAccine benefit-risk Collaboration in Europe (ADVANCE), a public-private consortium, implemented and tested a distributed network system for the generation of evidence on the benefits-risks of marketed vaccines in Europe. We tested the system by estimating the incidence rate (IR) of pertussis and pertussis-related complications in children vaccinated with acellular (aP) and whole-cell (wP) pertussis vaccine. Data from seven electronic databases from four countries (Denmark: AUH and SSI, Spain: SIDIAP and BIFAP, UK: THIN and RCGP RSC and Italy: Pedianet) were included in a retrospective cohort analysis. Exposure was defined as any pertussis vaccination (aP or wP). The follow-up time started 14 days after the first dose. Children who had received any pertussis vaccine from January 1990 to December 2015 were included (those who switched type, or had unknown type were excluded). The outcomes of interest were confirmed or suspected pertussis and pertussis-related pneumonia and generalised convulsions within one month of pertussis diagnosis and death within three months of pertussis diagnosis. The cohort comprised 2,886,367 children ≤5 years of age. Data on wP and aP vaccination were available in three and seven databases, respectively. The IRs (per 100,000 person-years) for pertussis varied largely and ranged between 0.15 (95% CI: 0.12; 0.19) and 1.15 (95% CI: 1.07; 1.23), and the trends over time was consistent with those observed from national surveillance databases for confirmed pertussis. The pertussis IRs decreased as the number of wP and aP vaccine doses increased. Pertussis-related complications were rare (89 pneumonia, 7 generalised convulsions and no deaths) and their relative risk (vs. non-pertussis) could not be reliably estimated. The study demonstrated the feasibility of the ADVANCE system to estimate the change in pertussis IRs following pertussis vaccination. Larger sample sizes would provide additional power to compare the risk for complications between children with and without pertussis. The feasibility of vaccine-type specific effectiveness studies may be considered in the future.
引用
- Tin Tin Htar M, de Ridder M, Braeye T, et al. Advance system testing: Vaccine benefit studies using multi-country electronic health data - The example of pertussis vaccination. Vaccine. 2019. PMID: 31677949. doi:10.1016/j.vaccine.2019.08.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。